Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

NewsGuard 100/100 Score

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

In the United States alone, more than 80 million adults have some form of CVD, many of whom have diabetes. The metabolic syndrome’s component symptoms’ underlying cause is insulin resistance (60% to 70%). More than 90% of patients with type 2 diabetes have signs of insulin resistance, which makes metabolic syndrome and type 2 diabetes very closely related in many CVD deaths.

Dr. Mehta reports that the best treatment for insulin resistance is for patients to improve their diet and exercise routine, and to take a combination of the various types of pharmocotherapy drugs to reduce high blood glucose levels after being thoroughly evaluated by a health care provider. The article cites a range of clinical trials to discuss their effects on management of metabolic syndrome and its key components. In order to reduce the risk of CVD, it must be diagnosed early in order to induce a therapeutic lifestyle change, and a full investigation of an individual’s health to uncover all metabolic syndrome components is necessary to initiate composite therapy.

Full text available at


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Restoring insulin sensitivity without TZD side effects